Mental Health and Neuroscience
Addressing an epidemic
Mental health disorders now constitute a national crisis. These conditions rank at the top for both high unmet needs and total healthcare spending. Yet, despite increased clinical development of new treatments, high quality insights from research to enable market adoption, broaden payer coverage, and personalize care are lacking or have been difficult to attain.
Mental health is complex. Accessing data shouldn’t be.
Understanding the complexities of these diseases and how varying factors affect access to treatments and care all shape how this specialty area is unique. It is exactly those same unique characteristics that drive our focus on bringing a dynamic new approach to mental health and neuroscience data to healthcare stakeholders.
Meet the largest Mental Health & Neuroscience data network in the U.S.
A comprehensive view of the patient journey from clinical development to the clinic
Bringing new treatments to market and delivering more precise care is challenging enough. Finding the data to empower your programs shouldn’t be. That’s why we built the largest mental health and neuroscience network in the U.S — rich with longitudinal clinical data and ready for addressing your most urgent questions.
Every condition presents its own unique challenges and opportunities. Select one of our sample datasets above to explore some of the features.
Depression patients with deep clinical data
Schizophrenia patients with deep clinical data
Bipolar patients with deep clinical data
MS patients with deep clinical data
*Data counts as of Q1 2022 ©OM1 Mental Health & Neurosciences Specialty Area
From evidence to insights
Burden of illness – mental health disorders in MS patients
Identify the population of MS patients with comorbid mental health conditions and understand unmet mental health intervention and impact on disease activity.
Evaluate treatment response and utilization in schizophrenia patients
Evaluate the side-effects (including weight gain and other risk factors) and costs associated with use of second generation antipsychotics.
Predict treatment resistance for depression
Predict which Treatment Resistant Depression (TRD) patients are at higher risk of excess resource utilization, using pre-treatment information to inform case management.
How we can help
Our specialized data and tools provide access to longitudinal patient journeys, critical outcomes and endpoints, and enable rapid and more in-depth analyses.
Fully utilize deep, clinical RWD to more efficiently design and conduct clinical trials such as:
- Mental Health: seeing where unmet needs in depression are greatest
- Neuroscience: uncovering subtypes in Alzheimer’s patients to determine which groups the protocol should be designed to enroll
Measure key safety outcomes of interest and support regulatory requirements such as:
- Mental Health: evaluating the impact of second-generation antipsychotics on weight changes in young adults
- Neuroscience: comparing the real-world safety profiles for patients on first- and second-generation antiepileptic drugs
Align with real world-based patient behaviors to measure:
- Mental Health: adherence to novel treatment approaches for treatment resistant depression
- Neuroscience: the potential reduction in T2 hyperintensity lesion burden in response to specific treatments for MS
Develop sound evidence for payers through deep clinical and linked claims data for a more complete view of clinical outcomes and utilization to assess:
- Mental Health: the cost effectiveness of early treatment interventions for major depression
- Neuroscience: the time to disability in MS patients as measured by EDSS in response to different treatments
RWD can help guide planning, forecasting, and improving brand performance such as:
- Mental Health: understanding the size of the market by segment in anxiety disorder subtypes that are best aligned with a brand’s positioning
- Neuroscience: qualifying the reasons for treatment discontinuation in Parkinson’s disease patients
Meet our mental health expert
Dr. Carl Marci is the Chief Psychiatrist and Managing Director of Mental Health and Neuroscience at OM1. Previously, he was Chief Psychiatrist and Chief Medical Officer at several venture backed health and technology companies.
Dr. Marci is board certified and is part-time staff at Massachusetts General Hospital and Assistant Professor of Psychiatry at Harvard Medical School, he completed two NIH Fellowships in neuroscience and has published numerous articles in peer-review science journals. He holds seven patents and is author of a forthcoming book on the impact of technology on the brain.
Dr. Marci is a graduate of Columbia University and Oxford University where he was a Rhodes Scholar. He then went to Harvard Medical School and graduated with honors; he is also the former Director of Social Neuroscience at Massachusetts General Hospital.
Award-Winning Research Team
Our team of award-winning researchers have authored more than 90 publications, including science posters, articles in peer-reviewed journals, white papers, and books.